文献速递浆细胞疾病

Cereblon增强子甲基化与多发性骨髓瘤IMiD耐药

Cereblon enhancer methylation and IMiD resistance in multiple myeloma.
PubMed 文献 · Blood · 2021-01-01

研究揭示多发性骨髓瘤中CRBN基因活性内含子增强子区域存在DNA高甲基化,该甲基化与CRBN表达下降显著相关,且在IMiD难治性MM中更为明显。DNA甲基转移酶抑制剂体外实验可诱导CRBN增强子去甲基化,并在2株MM细胞系中观察到对来那度胺治疗的增敏效应。提示异常CRBN DNA甲基化是IMiD耐药的新机制,并可能预测治疗反应。

要点

  • CRBN增强子区DNA高甲基化与CRBN表达下降显著相关。
  • 该高甲基化在IMiD难治性MM中更为明显。
  • DNA甲基转移酶抑制剂可去甲基化并增敏来那度胺。

核心结论

  • 异常CRBN DNA甲基化是MM中IMiD耐药的新机制,并可能预测IMiD反应。

研究设计与样本

  • 研究分析了CRBN活性内含子增强子区域的DNA甲基化,比较健康浆细胞与IMiD难治性MM,并行体外DNTMi实验。

主要发现

  • CRBN增强子区差异高甲基化在健康浆细胞中升高,在IMiD难治性MM中更明显。
  • 该区域甲基化与CRBN表达水平下降显著相关。
  • 体外DNTMi诱导CRBN增强子去甲基化,在2株MM细胞系中观察到对来那度胺的增敏效应。

临床怎么用

  • CRBN增强子甲基化有望作为预测IMiD反应的生物标志物。
  • DNA甲基转移酶抑制剂联合IMiD可能为克服耐药提供策略。

局限性

  • DNTMi增敏效应仅在2株MM细胞系体外实验中观察,尚需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cereblon is the direct binding target of the immunomodulatory drugs (IMiDs) that are commonly used to treat multiple myeloma (MM), the second most frequent hematologic malignancy. Patients respond well to initial treatment with IMiDs, but virtually all patients develop drug resistance over time, and the underlying mechanisms are poorly understood. We identified an as yet undescribed DNA hypermethylation in an active intronic CRBN enhancer. Differential hypermethylation in this region was found to be increased in healthy plasma cells, but was more pronounced in IMiD-refractory MM. Methylation significantly correlated with decreased CRBN expression levels. DNA methyltransferase inhibitor (DNTMi) in vitro experiments induced CRBN enhancer demethylation, and sensitizing effects on lenalidomide treatment were observed in 2 MM cell lines. Thus, we provide first evidence that aberrant CRBN DNA methylation is a novel mechanism of IMiD resistance in MM and may predict IMiD response prior to treatment.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Haertle L, Barrio S, Munawar U, et al. Cereblon enhancer methylation and IMiD resistance in multiple myeloma. Blood. 2021. PMID: 34115836. doi:10.1182/blood.2020010452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。